39 patents currently held

5 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

5 more records may belong here and await a decision; they are not counted.

The next term ends in Feb 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Feb 2028

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026202720282029203020312032 2033 2034 2035 2036 2037 2038 2039 2040 20412042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Organ-Specific Proteins and Methods of Their Use US 8,586,006

The most cited patent in this portfolio, cited by 265 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2030.

Ends Aug 2030 · High confidence Also notable

Compositions, Methods and Kits for Diagnosis of Lung Cancer US 9,304,137

Cited by 17 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.

Ends Dec 2032 · High confidence Also notable

Method for Reliable Classification of Samples in Clinical Diagnostics Using an Improved Method of Classification US 8,024,282

The largest patent family in this portfolio, 14 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028.

Ends Feb 2028 · High confidence

Formerly held, still cited

Notable

Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment with Immune Response Generating Therapies US 9,653,272

Cited by 14 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.

now held by Globeimmune, Inc.

Ends Feb 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Jan 2 to 28, 2027 · next Jan 2
1 fee due Mar 24, 2027
The maintenance fee for Blood Sample Separation Devices and Methods (US 10,422,729) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
1 fee due Apr 6, 2027
The maintenance fee for Method and system for determining whether a drug will be effective on a patient with a disease (US 9,152,758) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
1 fee due May 26, 2027
The maintenance fee for Predictive Test for Aggressiveness or Indolence of Prostate Cancer from Mass Spectrometry of Blood-Based Sample (US 10,489,550) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
2 fees due Jun 1 to 15, 2027 · next Jun 1
1 fee due Jul 14, 2027
The maintenance fee for Selected Reaction Monitoring Assays (US 10,534,002) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
2 fees due Aug 6 to 27, 2027 · next Aug 6
2 fees due Sep 8 to 29, 2027 · next Sep 8
1 fee due Oct 5, 2027
The maintenance fee for Compositions, Methods and Kits for Diagnosis of Lung Cancer (US 9,304,137) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 26 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Compositions, Methods and Kits for Diagnosis of Lung Cancer	6 in force	to Jul 2033
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings	3 in force	to Mar 2044
Predictive Test for Patient Benefit from Antibody Drug Blocking Ligand Activation of the T-Cell Programmed Cell Death 1 (PD-1) Checkpoint Protein and Classifier Development Methods	2 in force	to Jan 2037
Predictive Test for Aggressiveness or Indolence of Prostate Cancer from Mass Spectrometry of Blood-Based Sample	2 in force	to Apr 2036
Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof	2 in force	to Mar 2033

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,024,282	Method for Reliable Classification of Samples in Clinical Diagnostics Using an Improved Method of Classification In force Term ends Feb 11, 2028 · High confidence	In force	Term ends Feb 11, 2028	High confidence
US 9,152,758	Method and system for determining whether a drug will be effective on a patient with a disease In force Term ends Jun 16, 2028 · High confidence	In force	Term ends Jun 16, 2028	High confidence
US 8,586,006	Organ-Specific Proteins and Methods of Their Use In force Term ends Aug 24, 2030 · High confidence	In force	Term ends Aug 24, 2030	High confidence
US 9,091,651	Selected Reaction Monitoring Assays In force Term ends Dec 21, 2032 · High confidence	In force	Term ends Dec 21, 2032	High confidence
US 9,297,805	Compositions, Methods and Kits for Diagnosis of Lung Cancer In force Term ends Dec 21, 2032 · High confidence	In force	Term ends Dec 21, 2032	High confidence
US 9,304,137	Compositions, Methods and Kits for Diagnosis of Lung Cancer In force Term ends Dec 21, 2032 · High confidence	In force	Term ends Dec 21, 2032	High confidence
US 9,588,127	Compositions, Methods and Kits for Diagnosis of Lung Cancer In force Term ends Dec 21, 2032 · High confidence	In force	Term ends Dec 21, 2032	High confidence
US 10,338,074	Compositions, Methods and Kits for Diagnosis of Lung Cancer In force Term ends Dec 21, 2032 · High confidence	In force	Term ends Dec 21, 2032	High confidence
US 10,534,002	Selected Reaction Monitoring Assays In force Term ends Dec 21, 2032 · Medium confidence	In force	Term ends Dec 21, 2032	Medium confidence
US 11,193,935	Compositions, Methods and Kits for Diagnosis of Lung Cancer In force Term ends Dec 21, 2032 · Medium confidence	In force	Term ends Dec 21, 2032	Medium confidence

10 of 39 patents shown.

Pro members see all 39.

Pro members: see all 39 patents

Also on record, not counted in the 39: 5 patents in force now held by others · 14 patents ended · 3 applications pending · 19 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Biodesix, Inc.